Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 11, 16

Effects of Short-Term Treatment With Atorvastatin in Smokers With Asthma--A Randomized Controlled Trial

Affiliations
Randomized Controlled Trial

Effects of Short-Term Treatment With Atorvastatin in Smokers With Asthma--A Randomized Controlled Trial

Georgina Braganza et al. BMC Pulm Med.

Abstract

Background: The immune modulating properties of statins may benefit smokers with asthma. We tested the hypothesis that short-term treatment with atorvastatin improves lung function or indices of asthma control in smokers with asthma.

Methods: Seventy one smokers with mild to moderate asthma were recruited to a randomized double-blind parallel group trial comparing treatment with atorvastatin (40 mg per day) versus placebo for 4 weeks. After 4 weeks treatment inhaled beclometasone (400 μg per day) was added to both treatment arms for a further 4 weeks. The primary outcome was morning peak expiratory flow after 4 weeks treatment. Secondary outcome measures included indices of asthma control and airway inflammation.

Results: At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005]. There was no significant improvement with atorvastatin and inhaled beclometasone compared to inhaled beclometasone alone in outcome measures at 8 weeks.

Conclusions: Short-term treatment with atorvastatin does not alter lung function but may improve asthma quality of life in smokers with mild to moderate asthma.

Trial registration: Clinicaltrials.gov identifier: NCT00463827.

Figures

Figure 1
Figure 1
Flow of patients through study.
Figure 2
Figure 2
Change from baseline for both treatment groups in (a) morning PEF [L/min], (b) ACQ score, (c) AQLQ total score at 4 weeks. P values are for comparisons of the mean change from baseline between the two treatments.

Similar articles

See all similar articles

Cited by 20 PubMed Central articles

See all "Cited by" articles

References

    1. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168(11):1308–1311. doi: 10.1164/rccm.200304-503OC. - DOI - PubMed
    1. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226–230. doi: 10.1136/thorax.57.3.226. - DOI - PMC - PubMed
    1. Tomlinson JEM, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60(4):282–287. doi: 10.1136/thx.2004.033688. - DOI - PMC - PubMed
    1. Thomson N, Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med. 2009;15:39–45. doi: 10.1097/MCP.0b013e32831da894. - DOI - PubMed
    1. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6(5):358–370. doi: 10.1038/nri1839. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data

Feedback